Targeting RANKL Prevents Bone Loss, Improves Muscle Function and Extends Lifespan in Progeroid Mice

Sandra Freitas-Rodríguez and colleagues tested RANKL as a target in Hutchinson-Gilford progeria syndrome models. The study used Zmpste24−/− mice, a progeroid model with bone loss, muscle dysfunction, fibrosis, and shortened survival. Osteocyte-derived RANKL deletion reversed bone loss in long bones and vertebrae. The deletion also increased grip strength and endurance capacity and improved survival. A second experiment used a neutralizing antibody against RANKL. Antibody treatment restored bone mass, reduced muscle fibrosis, and extended lifespan in the progeroid mice. The abstract does not report sample sizes, effect sizes, confidence intervals, doses, or survival medians. The work is preclinical. It does not establish that RANKL inhibition extends lifespan in normal mice or humans. It also does not establish that denosumab, the human RANKL antibody, reproduces the findings in progeria or ordinary aging. Bone and muscle outcomes provide a plausible mechanistic bridge, but the model has a severe genetic aging phenotype that differs from usual human aging. The paper supports testing the pathway in disease-specific translational work. It does not justify off-label use for longevity.

Altogether, these findings support that targeting RANKL exerts a beneficial effect on both osseous and extra-osseous phenotypes of HGPS, suggesting the potential of this therapeutic approach to explore in the treatment of this disease.